- Home
- FORR vs VNDA Comparison
FORR vs VNDA Comparison
Compare FORR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | VNDA |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 231.0M |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FORR | VNDA |
|---|---|---|
| Price | $9.09 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 100.0K | ★ 1.2M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $12.05 |
| Revenue Next Year | N/A | $30.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.88 | $3.57 |
| 52 Week High | $12.75 | $9.91 |
Technical Indicators
Market Signals| Indicator | FORR | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 29.31 | 44.87 |
| Support Level | $8.72 | $3.57 |
| Resistance Level | $12.28 | $5.49 |
| Average True Range (ATR) | 0.68 | 0.28 |
| MACD | -0.23 | 0.06 |
| Stochastic Oscillator | 14.40 | 39.07 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.